The Medicines Company (MDCO)

Company Description

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in cardiovascular events such PTCA and stenting; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. Products under development include MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP.



The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 U.S.A
United States

Toll-free: 800-388-1183


Get BioInvest's perspective on the Medicines Company's CEO

Latest Company News

What You Must Know About The Medicines Company's (MDCO) Financial Strength Simply Wall St - 9 hours ago Mid-caps stocks, like The Medicines Company (NASDAQ:MDCO) with a market capitalization of $2.55B, aren't the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. The Medicines Company (MDCO) Given a $50.00 Price Target at Oppenheimer ... - Week Herald Analysts take a look at The Medicines Company (NASDAQ:MDCO) having this to say. - Finance News Daily [...]
Fri, Aug 18, 2017 8:03:00 PM, Continue reading at the source
Technical Indicators Alerts: Home Bancshares, Inc. (Conway, AR) (HOMB), The ... Post Analyst - 13 hours ago Home Bancshares, Inc. (Conway, AR) (NASDAQ:HOMB) traded at an unexpectedly low level on 08/17/2017 when the stock experienced a -3.32% loss to a closing price of $23.29. [...]
Fri, Aug 18, 2017 3:42:00 PM, Continue reading at the source
The Medicines Company (MDCO) Price Target Increased to $45.00 by Analysts at ... BNB Daily (blog) - Aug 16, 2017 The Medicines logo The Medicines Company (NASDAQ:MDCO) had its price target boosted by investment analysts at Citigroup Inc. from $43.00 to $45.00 in a note issued to investors on Wednesday, July 26th. The Medicines Company (MDCO) Retreats. Hold Signals Abound - StockNewsGazette [...]
Wed, Aug 16, 2017 6:56:00 AM, Continue reading at the source
Breaking Down: The Medicines Company (NASDAQ:MDCO) Stock Drop Below Support ... CML News - Aug 15, 2017 The Medicines Company has a one bull (extreme weakness) technical rating because it's trading below the 10 day, 50 day and 200 day simple moving averages while the 10-day moving average is below the 50-day moving average and the 50-day moving ... [...]
Tue, Aug 15, 2017 8:15:00 PM, Continue reading at the source
The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss Nasdaq - Aug 10, 2017 The Medicines Company MDCO reported second-quarter 2017 loss of $5.52 per share, massively wider than the Zacks Consensus Estimate of a loss of $1.29. The Medicines Company (MDCO) PT Lowered to $54 at Jefferies Following 2Q - Candriam Luxembourg SCA Boosts Position in The Medicines Company (NASDAQ:MDCO) - ExpressNewsline [...]
Thu, Aug 10, 2017 9:00:00 PM, Continue reading at the source
The Medicines (MDCO) Q2 2017 Results - Earnings Call Transcript Seeking Alpha - Aug 9, 2017 Good morning, ladies and gentlemen, and welcome to The Medicines Company Second Quarter 2017 Conference Call. At this time, all participants are in listen-only mode. [...]
Wed, Aug 09, 2017 7:08:00 PM, Continue reading at the source
The Medicines Company Reports Second Quarter 2017 Business and Financial Results Business Wire (press release) - Aug 9, 2017 The European Medicines Agency (EMA) has validated the Company's Marketing Authorization Application (MAA) for meropenem-vaborbactam, which confirms that the MAA submission is complete and initiates the Centralized Review process by the EMA's ... [...]
Wed, Aug 09, 2017 10:52:00 AM, Continue reading at the source
The Medicines Company Stock Attractively Priced Ahead Of FDA Decision Seeking Alpha - Jul 31, 2017 The Medicines Company (NASDAQ:MDCO) stock shows signs of stabilizing after seeing some steep decline in its value in the last couple of months. [...]
Mon, Jul 31, 2017 6:56:00 PM, Continue reading at the source
The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam ... Business Wire (press release) - Jul 25, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced positive results from an interim analysis of the TANGO-2 trial of its fixed-dose, investigational antibiotic combination, meropenem-vaborbactam. Late-stage study of The Medicines Co's antibiotic combo Vabomere stopped early ... - Seeking Alpha [...]
Tue, Jul 25, 2017 10:52:00 AM, Continue reading at the source
Sirukumab's Panel And US Decision For Medicines Company Seeking Alpha - Jul 21, 2017 And in the third quarter the Medicines Company (NASDAQ:MDCO) expects a US decision and phase III data for its antibiotic carbavance. [...]
Fri, Jul 21, 2017 2:15:00 PM, Continue reading at the source